NCT03719768 - Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

July 19, 2022

Study Completion Date

August 21, 2024

Conditions

Leptomeningeal MetastasesLeptomeningeal Disease

Interventions

DRUG

Avelumab

Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.

RADIATION

Whole Brain Radiotherapy

Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks

Trial Locations (1)

H. Lee Moffitt Cancer Center and Research Institute, Tampa